The goal of the Analytical Cytometry Core (ACC) is to provide the COHCCC members, through its facilities, leading-edge equipment and experienced operators to measure properties of cells and their components, isolate those cells and their components and present the data acquired for internal analysis and external review. Flow cytometry instrumentation available through this core resource includes: 3 high speed cell sorters (MoFlo, BD FACS Aria SORP and BD FACS Aria 111), and 4 analytical cytometers (Cyan, Gallios, LSR Fortessa and C6). The flow cytometry instrumentation provides investigators with the tools to analyze and isolate cells at speeds of up to 20,000 cells/second based on multiple fluorescent labels (up to 18) and light scatter properties with high yield (up to 90% based on speed) and extreme purity (99%). Additionally, the BD Aha 11 SORP is contained in a biosafety cabinet and allows users to sort live (potentially infectious) samples. All instrumentation in the ACC is subject to either daily (sorters and Fortessa) or weekly (Gallios, CyAn, and C6) quality control assessment and routine preventive maintenance and calibration. All data generated in the ACC is available through the institutional cyber-infrastructure network for further analysis and preparation for presentation or publication. Network based data processing software is offered by the core and a Laboratory Information Management System (LIMS) is being developed to help track experiment related meta data and archived file retrieval. Another key role of ACC is to provide flow cytometry training from basic theory, experimental design, software usage and operation of the cytometers to COHCCC members.
The overall goal of the Analytical Cytometry Core facility is to provide leading-edge equipment and experienced operators to measure properties of cells and their components, isolate those cells and present the data acquired for analysis and review. This goal promotes the Cancer Center's mission of developing innovative new disease-fighting strategies in the battle against cancer.
|Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590|
|Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137|
|Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29|
|Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587|
|Dietze, Eric C; Chavez, Tanya A; Seewaldt, Victoria L (2018) Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol 188:280-290|
|Ding, Yuan Chun; Adamson, Aaron W; Steele, Linda et al. (2018) Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer 17:187-195|
|Kurata, Jessica S; Lin, Ren-Jang (2018) MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA 24:966-981|
|Hardwick, Nicola R; Frankel, Paul; Ruel, Christopher et al. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res 24:1315-1325|
|Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37|
|Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:|
Showing the most recent 10 out of 1396 publications